Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | APOL1 | O14791 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | FABP7 | O15540 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | LGMN | Q99538 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958339 | 0.84 | PDE4D (0.36) | PDE4DPIK3CDAPOL1BACE1TNF | |
| SCHEMBL11830010 | 0.83 | SERPINE1 (0.35) | L3MBTL1FABP7FABP5SERPINE1 | |
| SCHEMBL9228141 | 0.83 | — | — | |
| SCHEMBL31452884 | 0.82 | GABRP (0.42) | PDE4DAPOL1KAT2BBAZ2BBACE1 | |
| Iodide SCHEMBL28946787 | 0.80 | SERPINE1 (0.34) | L3MBTL1FABP7FABP5SERPINE1 | |
| SCHEMBL28037226 | 0.80 | SERPINE1 (0.34) | L3MBTL1FABP7FABP5SERPINE1 | |
| SCHEMBL30142098 | 0.78 | CHRM2 (0.34) | PDE4DPIK3CD | |
| SCHEMBL17423456 | 0.78 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL16784670 | 0.76 | CES2 (0.48) | FABP7FABP5 | |
| SCHEMBL2978095 | 0.75 | CHRNB2 (0.53) | APOL1KAT2BBAZ2BBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300953-B2 | Process for preparing nitrile compound, carboxylic acid compound or carboxylic acid ester compound | UBE INDUSTRIES, LTD (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | UBE INDUSTRIES, LTD. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1671937-A1 | METHOD FOR PRODUCING NITRILE COMPOUND, CARBOXYLIC ACID COMPOUND OR CARBOXYLATE COMPOUND | Ube Industries, Ltd. (JP) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | CBR1, ALDH18A1, ME1 | PDE4D 4104/4885PIK3CD 3254/4885APOL1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.